Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment – oxaliplatin subscale: a prospective cohort study

• Published in: BMC cancer Vol. 23; no. 1; pp. 1 - 1109
• Main Authors: Gu, Zhancheng, Chen, Chen, Gu, Jialin, Song, Ziwei, Wei, Guoli, Cai, Guoxiang, Shu, Qijin, Zhu, Lingjun, Zhu, Weiyou, Deng, Haibin, Li, Sheng, Chen, Aifei, Yin, Yue, Wu, Qiulan, Zhu, Hongyu, Li, Guochun, Dai, Anwei, Huo, Jiege
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 14-11-2023; BioMed Central; BMC
• Subjects: Analysis; Antimitotic agents; Antineoplastic agents; Assessment tool; Ataxia; Cancer; Cancer therapies; Care and treatment; Chemotherapy; Complications and side effects; Correlation analysis; Diagnosis; Factor analysis; Literature reviews; Molecular mechanics; Neurologic manifestations of general diseases; Neurotoxicity; Oncology; Oxaliplatin; Oxaliplatin-induced peripheral neuropathy (OIPN); Patient-reported outcome; Patients; Peripheral neuropathy; Polyneuropathies; Population studies; Questionnaires; Reliability and validity analysis; Risk factors; Sensitivity; Validity; China
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-023-11541-7

Background Current chemotherapy-induced peripheral neuropathy (CIPN) assessment tools mostly have poor sensitivity and weak anti-interference, so that it is sometimes difficult to provide substantive guidance for clinical intervention. This study aimed to develop an assessment tool dedicated for oxaliplatin to address these limitations. Methods This study screened 445 OIPN-related literatures for producing a symptom list, and developed the questionnaire module through expert supplement, item generation, content correlation analysis, pre-testing, and item improvement. The validation phase used a Chinese population-based prospective cohort study from June 2021 to July 2022. Patients were requested to complete the tested questionnaire, QLQ-CIPN20 and the CTCAE grading one day before cycles 2-6 of chemotherapy. Cronbach's [alpha] coefficient and intraclass correlation coefficient (ICC) were calculated for the internal consistency and stability analysis, respectively. Exploratory factor analysis was conducted to investigate the construct validity. The correlations among the tested questionnaire, QLQ-CIPN20 and CTCAE were compared for the criterion validity analysis. Wilcoxon signed-rank sum test was utilized to compare the sensitivity between the tested questionnaire and QLQ-CIPN20. Result A 20-item CIPN assessment tool named chemotherapy-induced peripheral neuropathy integrated assessment - oxaliplatin subscale (CIPNIA-OS) was developed. The validation phase included 186 patients. Cronbach's [alpha] coefficient of CIPNIA-OS was 0.764 (> 0.7), and ICC was 0.997 (between 0.9 and 1). The structure of CIPNIA-OS containing seven factors was examined. The correlation coefficient between CIPNIA-OS and CTCAE was 0.661 (95%CI 0.623 to 0.695), which was significantly higher than that between QLQ-CIPN20 and CTCAE (0.417, 95%CI 0.363 to 0.469, p < 0.01). Besides, the total score of CIPNIA-OS was mostly higher than QLQ-CIPN20, with an average difference of 2.189 (CI 95% 2.056 to 2.322), and the difference gradually expanded with the progress of chemotherapy (p < 0.05). Conclusion This study developed an original CIPN questionnaire which was dedicated for OIPN assessment. It was a comprehensive tool that covered acute OIPN symptoms and integrated features from several proven CIPN assessment tools. The validation results supported that CIPNIA-OS had satisfactory reliability, stability, construct, criterion validity, and was more accuracy and sensitive than QLQ-CIPN20 in the evaluation of OIPN. Keywords: Oxaliplatin-induced peripheral neuropathy (OIPN), Assessment tool, Reliability and validity analysis, Sensitivity, Patient-reported outcome